Iovance Biotherapeutics, Inc.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Other Names/Subsidiaries
- Genesis Biopharma
- Lion Biotechnologies
Latest on Iovance Biotherapeutics, Inc.
In Europe’s complex and cost-conscious health care environment, securing timely and sustainable market access for innovative therapies is both a strategic priority and a growing challenge. For pharma
Gilead Sciences could learn this week whether the European Medicines Agency will recommend that lenacapavir should be approved for marketing as a twice-yearly preventative option for HIV in the EU as
Gilead Sciences’ Kite division is stepping into cell therapy for solid tumors with encouraging early efficacy data in one of the toughest of all cancers to treat, having presented Phase I results for
With one approved therapy in the US and approximately 75 more in the pipeline, tumor infiltrating lymphocyte (TIL) treatments are a promising new approach to cancer immunotherapy, particularly for sol